



SIgN SEMINAR

Hosted by Dr Shi-Yong NEO

Jeffrey S. MILLER, MD

Professor of Medicine,
Hematology, Oncology & Transplantation,
University of Minnesota, USA

Off-The-Shelf Targeted NK Cell Therapies To Treat Cancer

The development of NK cell-mediated therapies is an emerging treatment modality within the immune-oncology space. Robust killing capacities, low risk of graft versus host disease (GvHD) and adverse toxicity are driving promising clinical responses to adoptive NK cell transfers observed in multiple cancers. Dr. Miller will review individual haploidentical NK cells now progressing to off-the-shelf iPSC derived NK cell products with multiple gene edits and immune engagers to make NK cells antigen-specific in vivo.